All > Mens Health > Hemophilia

Damoctocog alfa pegol (Jivi, BAY94-9027) for Hemophilia A

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Hemophilia A+3 MoreDamoctocog alfa pegol (Jivi, BAY94-9027) - Biological
Eligibility
7 - 11
Male
What conditions do you have?
Select

Study Summary

This trial is looking for a better way to treat hemophilia A, a genetic disorder where the body does not create enough of a protein called clotting factor 8 (FVIII) present in the blood.

Eligible Conditions
  • Hemophilia A
  • Treatment of Bleeding
  • Prophylaxis of Bleeding
  • Children

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Similar Trials

1
Factor IX
1
efanesoctocog alfa (BIVV001)
1
Valoctocogene roxaparvovec

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: Up to 24 months

Month 6
Anti-drug antibody (ADA) development
The number of participants with confirmed Factor VIII inhibitors
Up to 24 months
Annualized bleeding rate (ABR)
BAY94-9027 consumption
Number of infusions/month and year (Annualized Infusion Rate)
Up to 6 months
AESI (hypersensitivity and loss of efficacy) associated with the first 4 exposure days leading to discontinuation
Adverse drug reactions (ADRs)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
Factor IX
1
efanesoctocog alfa (BIVV001)
1
Valoctocogene roxaparvovec

Side Effects for

pd vWF/FVIII
17%Pyrexia
12%Nasopharyngitis
8%Cough
8%Upper respiratory tract infection
6%Vomiting
6%Viral infection
5%Bronchitis
5%Diarrhoea
3%Anaemia
2%Subcutaneous haematoma
2%Pharyngitis
2%Head Injury
1%Road traffic accident
1%Vessel puncture site haemorrhage
1%Haemorrhagic anaemia
1%Hypersomnia
1%Haemorrhage intracranial
1%Skin haemorrhage
1%Urinary tract infection
1%Cerebral haemorrhage
1%Nausea
1%Haemorrhage
1%Pancytopenia
1%Seizure
1%Speech disorder developmental
1%Abdominal wall haemorrhage
1%Epidural Haemorrage
1%Haematemesis
1%Hemiparesis
1%Circumcision
1%Haemarthrosis
1%Hemiplegia
1%Lymphadenopathy
1%Muscle haemorrhage
1%Subdural haematoma
This histogram enumerates side effects from a completed 2015 Phase 4 trial (NCT01064284) in the pd vWF/FVIII ARM group. Side effects include: Pyrexia with 17%, Nasopharyngitis with 12%, Cough with 8%, Upper respiratory tract infection with 8%, Vomiting with 6%.

Trial Design

1 Treatment Group

Main study (Part A) and the extension study (Part B)
1 of 1

Experimental Treatment

33 Total Participants · 1 Treatment Group

Primary Treatment: Damoctocog alfa pegol (Jivi, BAY94-9027) · No Placebo Group · Phase 3

Main study (Part A) and the extension study (Part B)
Biological
Experimental Group · 1 Intervention: Damoctocog alfa pegol (Jivi, BAY94-9027) · Intervention Types: Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Damoctocog alfa pegol
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 24 months

Who is running the clinical trial?

BayerLead Sponsor
2,150 Previous Clinical Trials
23,875,094 Total Patients Enrolled
59 Trials studying Hemophilia A
4,950 Patients Enrolled for Hemophilia A

Eligibility Criteria

Age 7 - 11 · Male Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are willing and able to complete training in the use of the EPD and to document infusions during the study.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top